|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2016. CA Cancer J Clin. 66:7–30. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Cuzick J, Sestak I, Baum M, Buzdar A,
Howell A, Dowsett M and Forbes JF: ATAC/LATTE investigators: Effect
of anastrozole and tamoxifen as adjuvant treatment for early-stage
breast cancer: 10-year analysis of the ATAC trial. Lancet Oncol.
11:1135–1141. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Perez EA, Romond EH, Suman VJ, Jeong JH,
Davidson NE, Geyer CE Jr, Martino S, Mamounas EP, Kaufman PA and
Wolmark N: Four-year follow-up of trastuzumab plus adjuvant
chemotherapy for operable human epidermal growth factor receptor
2-positive breast cancer: Joint analysis of data from NCCTG N9831
and NSABP B-31. J Clin Oncol. 29:3366–3373. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Slamon D, Eiermann W, Robert N, Pienkowski
T, Martin M, Press M, Mackey J, Glaspy J, Chan A, Pawlicki M, et
al: Breast Cancer International Research Group: Adjuvant
trastuzumab in HER2-positive breast cancer. N Engl J Med.
365:1273–1283. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Palmieri C and Jones A: The 2011 EBCTCG
polychemotherapy overview. Lancet. 379:390–392. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Gonzalez-Angulo AM, Morales-Vasquez F and
Hortobagyi GN: Overview of resistance to systemic therapy in
patients with breast cancer. Adv Exp Med Biol. 608:1–22. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Jackson SP: DNA-dependent protein kinase.
Int J Biochem Cell Biol. 29:935–938. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Goodwin JF and Knudsen KE: Beyond DNA
repair: DNA-PK function in cancer. Cancer Discov. 4:1126–1139.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Hsu FM, Zhang S and Chen BP: Role of
DNA-dependent protein kinase catalytic subunit in cancer
development and treatment. Transl Cancer Res. 1:22–34.
2012.PubMed/NCBI
|
|
10
|
Zhang L, Komurov K, Wright WE and Shay JW:
Identification of novel driver tumor suppressors through functional
interrogation of putative passenger mutations in colorectal cancer.
Int J Cancer. 132:732–737. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zhang L, Kim S, Jia G, Buhmeida A, Dallol
A, Wright WE, Fornace AJ, Al-Qahtani M and Shay JW: Exome
sequencing of normal and isogenic transformed human colonic
epithelial cells (HCECs) reveals novel genes potentially involved
in the early stages of colorectal tumorigenesis. BMC Genomics. 16
Suppl 1:S82015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Mukherjee B, McEllin B, Camacho CV,
Tomimatsu N, Sirasanagandala S, Nannepaga S, Hatanpaa KJ, Mickey B,
Madden C, Maher E, et al: EGFRvIII and DNA double-strand break
repair: A molecular mechanism for radioresistance in glioblastoma.
Cancer Res. 69:4252–4259. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Shintani S, Mihara M, Li C, Nakahara Y,
Hino S, Nakashiro K and Hamakawa H: Up-regulation of DNA-dependent
protein kinase correlates with radiation resistance in oral
squamous cell carcinoma. Cancer Sci. 94:894–900. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Hartley KO, Gell D, Smith GC, Zhang H,
Divecha N, Connelly MA, Admon A, Lees-Miller SP, Anderson CW and
Jackson SP: DNA-dependent protein kinase catalytic subunit: A
relative of phosphatidylinositol 3-kinase and the ataxia
telangiectasia gene product. Cell. 82:849–856. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Davis AJ, Chen BP and Chen DJ: DNA-PK: A
dynamic enzyme in a versatile DSB repair pathway. DNA Repair
(Amst). 17:21–29. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Lee KJ, Lin YF, Chou HY, Yajima H, Fattah
KR, Lee SC and Chen BP: Involvement of DNA-dependent protein kinase
in normal cell cycle progression through mitosis. J Biol Chem.
286:12796–12802. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Shang ZF, Huang B, Xu QZ, Zhang SM, Fan R,
Liu XD, Wang Y and Zhou PK: Inactivation of DNA-dependent protein
kinase leads to spindle disruption and mitotic catastrophe with
attenuated checkpoint protein 2 Phosphorylation in response to DNA
damage. Cancer Res. 70:3657–3666. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Lee HS, Yang HK, Kim WH and Choe G: Loss
of DNA-dependent protein kinase catalytic subunit (DNA-PKcs)
expression in gastric cancers. Cancer Res Treat. 37:98–102. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Ren F, Yang ZL, Tan X, Liu D, Zou Q, Yuan
Y, Li J, Liang L, Zeng G and Chen S: DNA-PKcs and Ku70 are
predictive markers for poor prognosis of patients with gall bladder
malignancies. Appl Immunohistochem Mol Morphol. 22:741–747. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Hosoi Y, Watanabe T, Nakagawa K, Matsumoto
Y, Enomoto A, Morita A, Nagawa H and Suzuki N: Up-regulation of
DNA-dependent protein kinase activity and Sp1 in colorectal cancer.
Int J Oncol. 25:461–468. 2004.PubMed/NCBI
|
|
21
|
Tonotsuka N, Hosoi Y, Miyazaki S, Miyata
G, Sugawara K, Mori T, Ouchi N, Satomi S, Matsumoto Y, Nakagawa K,
et al: Heterogeneous expression of DNA-dependent protein kinase in
esophageal cancer and normal epithelium. Int J Mol Med. 18:441–447.
2006.PubMed/NCBI
|
|
22
|
Xing J, Wu X, Vaporciyan AA, Spitz MR and
Gu J: Prognostic significance of ataxia-telangiectasia mutated,
DNA-dependent protein kinase catalytic subunit, and Ku
heterodimeric regulatory complex 86-kD subunit expression in
patients with nonsmall cell lung cancer. Cancer. 112:2756–2764.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Holgersson A, Erdal H, Nilsson A,
Lewensohn R and Kanter L: Expression of DNA-PKcs and Ku86, but not
Ku70, differs between lymphoid malignancies. Exp Mol Pathol.
77:1–6. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Kotula E, Berthault N, Agrario C, Lienafa
MC, Simon A, Dingli F, Loew D, Sibut V, Saule S and Dutreix M:
DNA-PKcs plays role in cancer metastasis through regulation of
secreted proteins involved in migration and invasion. Cell Cycle.
14:1961–1972. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Goodwin JF, Kothari V, Drake JM, Zhao S,
Dylgjeri E, Dean JL, Schiewer MJ, McNair C, Jones JK, Aytes A, et
al: DNA-PKcs-mediated transcriptional regulation drives prostate
cancer progression and metastasis. Cancer Cell. 28:97–113. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Burdine LJ, Burdine MS, Moreland L, Fogel
B, Orr LM, James J, Turnage RH and Tackett AJ: Proteomic
identification of DNA-PK involvement within the RET signaling
pathway. PLoS One. 10:e01279432015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Elliott SL, Crawford C, Mulligan E,
Summerfield G, Newton P, Wallis J, Mainou-Fowler T, Evans P,
Bedwell C, Durkacz BW, et al: Mitoxantrone in combination with an
inhibitor of DNA-dependent protein kinase: A potential therapy for
high risk B-cell chronic lymphocytic leukaemia. Br J Haematol.
152:61–71. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Stronach EA, Chen M, Maginn EN, Agarwal R,
Mills GB, Wasan H and Gabra H: DNA-PK mediates AKT activation and
apoptosis inhibition in clinically acquired platinum resistance.
Neoplasia. 13:1069–1080. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Vivanco I and Sawyers CL: The
phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev
Cancer. 2:489–501. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
30
|
Ciszewski WM, Tavecchio M, Dastych J and
Curtin NJ: DNA-PK inhibition by NU7441 sensitizes breast cancer
cells to ionizing radiation and doxorubicin. Breast Cancer Res
Treat. 143:47–55. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Munck JM, Batey MA, Zhao Y, Jenkins H,
Richardson CJ, Cano C, Tavecchio M, Barbeau J, Bardos J, Cornell L,
et al: Chemosensitization of cancer cells by KU-0060648, a dual
inhibitor of DNA-PK and PI-3K. Mol Cancer Ther. 11:1789–1798. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Noguchi T, Shibata T, Fumoto S, Uchida Y,
Mueller W and Takeno S: DNA-PKcs expression in esophageal cancer as
a predictor for chemoradiation therapeutic sensitivity. Ann Surg
Oncol. 9:1017–1022. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Söderlund Leifler K, Queseth S, Fornander
T and Askmalm MS: Low expression of Ku70/80, but high expression of
DNA-PKcs, predict good response to radiotherapy in early breast
cancer. Int J Oncol. 37:1547–1554. 2010.PubMed/NCBI
|
